Treatment of chronic hepatitis C with PegIFN-alfa2b and ribavirin: Outcome for migrants from GUS countries is associated with higher SVR-rates compared to German patients within a…
S Mauss, E Zehnter, MP Manns, G Teuber, T Dahhan, U Meyer, T Witthöft, B Möller, N Dikopoulos, J Brack, M Bilzer, G Tossing, D Hüppe · Zeitschrift für Gastroenterologie · 2010 · Heft 08
Bibliografische Angaben
Zusammenfassung
Aims: A combination of pegylated interferon-alfa (PegIFN-alfa) plus ribavirin (RBV) is the current standard of care for treatment of chronic hepatitis C. Within a German multicentric observational study the largest group of migrants came from Ex-USSR countries. As higher SVR-rates have been observed in the group of GUS-migrants compared to German patients (Mauss et al, Abstract GASL 2010), we investigated if this finding was due to the significant difference in age within the two groups and stratified by age categories. Methods: Between 9/2003 and 5/2009, 279 active sites treated a total of 3852 patients with we…
